<h1>Legal risks of exosome- and mRNA hair regrowth claims: regulatory compliance, patent strength, product liability, and false-advertising exposure</h1> A healthcare provider announced a novel exosome- and mRNA-based hair regrowth treatment, asserting FDA approval, a US patent, non-invasiveness, absence of side effects, and rapid results in four sessions while claiming cost and efficacy superiority over competitors. Legally significant points include regulatory compliance of therapeutic and marketing claims (substantiation required by drug/medical device regulators and advertising/consumer-protection authorities), potential product-liability exposure if adverse effects emerge, enforceability and scope of the asserted US patent, and antitrust/false-advertising risks from comparative pricing and superiority statements. The communication appears as a press release with a distributor disclaimer.